<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00244101</url>
  </required_header>
  <id_info>
    <org_study_id>CHRMS 03-233</org_study_id>
    <nct_id>NCT00244101</nct_id>
  </id_info>
  <brief_title>Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome</brief_title>
  <official_title>Delivery Room Management of Premature Infants at High Risk of Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vermont Oxford Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vermont Oxford Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The best mode of delivery room stabilization for premature infants at high risk for
      respiratory distress syndrome is unknown. The protocol evaluates the impact of three distinct
      methods of post-delivery stabilization and subsequent early respiratory care on chronic lung
      disease and survival in premature infants at high risk for respiratory distress syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The &quot;Delivery room management of premature infants at high risk of respiratory distress
      syndrome&quot; protocol compares three distinct methods of post-delivery stabilization and
      subsequent early respiratory care on chronic lung disease and survival in premature infants
      at high risk of respiratory distress syndrome. The three approaches to post-delivery care
      include:

        1. Intubation, prophylactic surfactant administration shortly after delivery, and
           subsequent stabilization on ventilator support.

        2. Early stabilization on nasal continuous positive airway pressure (NCPAP) with selective
           intubation and surfactant administration for clinical indications.

        3. Intubation, prophylactic surfactant administration shortly after delivery and rapid
           extubation to nasal CPAP.

      The primary null hypothesis for this study is that no difference will be found in chronic
      lung disease and/or mortality at 36 weeks adjusted age in premature infants at high risk of
      RDS, depending on the method of post-delivery stabilization.

      The study is a randomized, multicenter trial conducted at participating Vermont Oxford
      Network Centers. Participating centers will demonstrate competency in the use of nasal CPAP
      by successfully completing a web-based, educational program and utilizing nasal CPAP in a
      minimum of 20 infants in their NICU.

      Infants likely to be delivered to women presenting to a participating Vermont Oxford Network
      Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks will be
      eligible for inclusion. Specific inclusion criteria that must be met prior to randomization
      include:

        1. imminent delivery

        2. no potentially life-threatening congenital anomaly or genetic syndrome

        3. no known lung maturity

        4. antenatal steroid status known

        5. written and informed consent obtained prior to delivery.

      Exclusion criteria will include:

        1. stillborn infants (Apgar score of 0 at one minute of age) or

        2. infants noted to have a potentially life-threatening congenital anomaly or genetic
           syndrome noted immediately after delivery.

      Eligible infants will have consent obtained prior to delivery. They will be stratified into
      two groups: 26 + 0 to 27 + 6 weeks gestation and 28 + 0 to 29 + 6 weeks gestation. Shortly
      before delivery, infants will be randomized to one of the three stabilization strategies
      detailed below:

        1. Intubation, prophylactic surfactant administration shortly after delivery, and
           subsequent stabilization on ventilator support (PS group).

        2. Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected
           intubation and surfactant administration for clinical indications (NCPAP group).

        3. Intubation, prophylactic surfactant administration shortly after delivery, and rapid
           extubation to nasal CPAP (ISX group).

      Infants requiring intubation for respiratory failure during this study (in any of the three
      groups) may be stabilized on either conventional or high-frequency ventilation. Specific
      criteria regarding target ranges for blood gases and indications for extubation, subsequent
      surfactant dosing, management of extubation, and criteria for reintubation, are all detailed
      in the protocol.

      The primary outcome measure is chronic lung disease (defined as documented requirement for
      supplemental oxygen or respiratory support) or mortality at 36 weeks adjusted age. Secondary
      outcome measures include a variety of clinical outcomes, as well as issues regarding duration
      of hospital stay and other resource utilization. Long-term outcomes will be measured by a
      health care questionnaire at two years of age. A sample size of over 895 infants will be
      required to demonstrate a 25% reduction in the risk of chronic lung disease at 36 weeks
      adjusted age.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Death or Chronic Lung Disease</measure>
    <time_frame>at 36 weeks postmenstrual age</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Death</measure>
    <time_frame>36 weeks adjusted age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complications of Prematurity</measure>
    <time_frame>prior to hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of Ventilator Support</measure>
    <time_frame>prior to hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in Hospital</measure>
    <time_frame>prior to hospital discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parental Questionnaire for Health Status</measure>
    <time_frame>at 24 months of age</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">648</enrollment>
  <condition>Respiratory Distress Syndrome, Newborn</condition>
  <arm_group>
    <arm_group_label>PS Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NCPAP Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ISX Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PS Group</intervention_name>
    <description>Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.</description>
    <arm_group_label>PS Group</arm_group_label>
    <other_name>Prophylactic Surfactant Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NCPAP Group</intervention_name>
    <description>Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.</description>
    <arm_group_label>NCPAP Group</arm_group_label>
    <other_name>Nasal CPAP group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISX Group</intervention_name>
    <description>Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.</description>
    <arm_group_label>ISX Group</arm_group_label>
    <other_name>Intubation, Surfactant Administration, Extubation to Nasal CPAP. ENSURE.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Infants likely to be delivered to women presenting to a participating Vermont Oxford
        Network Center at high risk of premature delivery at gestational age 26 + 0 to 29 + 6 weeks
        will be eligible for inclusion. Specific inclusion criteria that must be met prior to
        randomization include:

          1. Imminent delivery

          2. No potentially life-threatening congenital anomaly or genetic syndrome

          3. No known lung maturity

          4. Antenatal steroid status known

          5. Written, informed consent obtained (on admission or prior to delivery).

        Exclusion Criteria:

          1. Stillborn (Apgar score of 0 at one minute of age)

          2. Noted to have a potentially life-threatening congenital anomaly or genetic syndrome
             noted immediately after delivery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>26 Weeks</minimum_age>
    <maximum_age>29 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roger F Soll, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Clinical Trials, Vermont Oxford Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Dunn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief of Newborn and Developmental Pediatrics, Sunnybrook and Women's Hospital, Toronto, Ontario, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vermont Oxford Network</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vtoxford.org/home.aspx?p=research/drm/index.htm</url>
    <description>Click here for more information about the Delivery Room Management Trial.</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2005</study_first_submitted>
  <study_first_submitted_qc>October 24, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2005</study_first_posted>
  <results_first_submitted>August 16, 2012</results_first_submitted>
  <results_first_submitted_qc>August 16, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2012</results_first_posted>
  <last_update_submitted>August 16, 2012</last_update_submitted>
  <last_update_submitted_qc>August 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prematurity</keyword>
  <keyword>respiratory distress syndrome</keyword>
  <keyword>surfactant</keyword>
  <keyword>nasal continuous positive airway pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Surfactants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PS Group</title>
          <description>Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.</description>
        </group>
        <group group_id="P2">
          <title>NCPAP Group</title>
          <description>Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.</description>
        </group>
        <group group_id="P3">
          <title>ISX Group</title>
          <description>Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="223"/>
                <participants group_id="P3" count="216"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="209"/>
                <participants group_id="P2" count="223"/>
                <participants group_id="P3" count="216"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PS Group</title>
          <description>Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.</description>
        </group>
        <group group_id="B2">
          <title>NCPAP Group</title>
          <description>Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.</description>
        </group>
        <group group_id="B3">
          <title>ISX Group</title>
          <description>Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="209"/>
            <count group_id="B2" value="223"/>
            <count group_id="B3" value="216"/>
            <count group_id="B4" value="648"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="216"/>
                    <measurement group_id="B4" value="648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="1.1"/>
                    <measurement group_id="B2" value="28.1" spread="1.3"/>
                    <measurement group_id="B3" value="28.1" spread="1.1"/>
                    <measurement group_id="B4" value="28.0" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="115"/>
                    <measurement group_id="B4" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                    <measurement group_id="B2" value="124"/>
                    <measurement group_id="B3" value="101"/>
                    <measurement group_id="B4" value="316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="209"/>
                    <measurement group_id="B2" value="223"/>
                    <measurement group_id="B3" value="216"/>
                    <measurement group_id="B4" value="648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Death or Chronic Lung Disease</title>
        <time_frame>at 36 weeks postmenstrual age</time_frame>
        <population>intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>PS Group</title>
            <description>Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.</description>
          </group>
          <group group_id="O2">
            <title>NCPAP Group</title>
            <description>Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.</description>
          </group>
          <group group_id="O3">
            <title>ISX Group</title>
            <description>Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.</description>
          </group>
        </group_list>
        <measure>
          <title>Death or Chronic Lung Disease</title>
          <population>intention to treat analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="209"/>
                <count group_id="O2" value="223"/>
                <count group_id="O3" value="216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PS group used as standard of care. Relative risk and 95 % CI calculated for NCPAP group and ISX group compared to PS group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Risk Ratio (RR)</param_type>
            <param_value>.365</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>.05</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Death</title>
        <time_frame>36 weeks adjusted age</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complications of Prematurity</title>
        <time_frame>prior to hospital discharge</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days of Ventilator Support</title>
        <time_frame>prior to hospital discharge</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Days in Hospital</title>
        <time_frame>prior to hospital discharge</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Parental Questionnaire for Health Status</title>
        <time_frame>at 24 months of age</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prophylactic Surfactant</title>
          <description>Prophylactic surfactant followed by mechanical ventilation</description>
        </group>
        <group group_id="E2">
          <title>Surfactant Extubated to nCPAP</title>
          <description>prophylactic surfactant with rapid extubation to bubble nCPAP</description>
        </group>
        <group group_id="E3">
          <title>NCPAP</title>
          <description>initial management with bubble nCPAP and selective surfactant treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="216"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Roger F. Soll, MD</name_or_title>
      <organization>Vermont Oxford Network</organization>
      <phone>802 865 4814 ext 212</phone>
      <email>roger.soll@vtmednet.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

